Schwartz Center Receives $500,000 Grant from the Amgen Foundation

AmgenThe Schwartz Center for Compassionate Healthcare, a Boston-based nonprofit dedicated to strengthening the relationship between patients and their healthcare providers, today announced it has received a $500,000 grant from the Amgen Foundation. This grant will go toward the planned expansion of Schwartz Center Rounds® and to support the launch of a National Consensus Project.

These initiatives aim to make compassionate, patient-centered care a national healthcare priority. The Schwartz Center Rounds allow caregivers from multiple disciplines to come together on a regular basis to discuss the most challenging emotional and social issues they face in caring for patients. The National Consensus Project will convene a broad range of stakeholders to define compassionate care, develop best practices to ensure that this type of care is provided, and develop a plan to implement these core principles and best practices.

"This grant, the largest in our history, will make it possible for us to double the number of Rounds sites overall in California and the Washington, D.C. area and to expand the program to additional cancer centers throughout the United States," said Julie Rosen, executive director, Schwartz Center. "It will also allow us to launch our National Consensus Project to ensure that all patients receive compassionate care something that is particularly important now as our healthcare system is changing and providers are under such intense pressure to reduce costs, while improving quality."

The Amgen Foundation, based in Thousand Oaks, is the philanthropic arm of Amgen, the world's largest biotechnology company. A key area of focus for the Foundation is ensuring quality of care and access for patients with an emphasis on patient empowerment and reducing healthcare disparities.

"The Schwartz Center provides health professionals with a practical avenue to reflect upon and manage through the complexities inherent in providing care for seriously ill patients," said Jean Lim Terra, president, Amgen Foundation. "We are proud to support these programs that empower healthcare professionals to truly fulfill their mission to deliver quality care for patients."

Schwartz Center Rounds are currently held at 247 hospitals and other healthcare institutions in 35 states in the United States (U.S.) and at 11 hospitals in the United Kingdom. A comprehensive evaluation has shown that caregivers who attend multiple Rounds sessions feel more compassionate toward their patients and less stressed. Attendees also report that the program has improved teamwork and resulted in system changes.

Through its National Consensus Project, the Schwartz Center will launch a national conversation about the importance of compassionate care by convening healthcare professionals, patients, policymakers, educators and researchers to reach expert consensus on a definition of compassionate care, develop a set of organizational and institutional best practices to ensure that this type of care is provided, and develop a plan for disseminating these core principles and best practices.

According to Rosen, "Our vision is a healthcare system in which all patients receive compassionate, patient- and family-centered care, and all caregivers are supported to provide it. We are grateful to the Amgen Foundation for helping us to make this vision a reality."

The Schwartz Center's vision is based on the experience of Ken Schwartz, a well-known Boston healthcare attorney who died of lung cancer at the age of 40 and found that what mattered to him most as a patient was the compassionate care he received from his caregivers, which he wrote in the Boston Globe Magazine "made the unbearable bearable." He founded the Schwartz Center in 1995 to ensure that all patients receive compassionate care.

In a national survey conducted by the Schwartz Center in 2010, more than 80 percent of patients said they believe that effective communication and emotional support the essential elements of compassionate care make a difference in how well patients recover from illness and can even make a difference in whether a patient lives or dies. Yet, patients' ratings of how well their caregivers demonstrated these attributes fell short of their expectations and only about half of patients rated the U.S. healthcare system as a compassionate one.

The Amgen Foundation has been a long-time supporter of the Schwartz Center, having previously provided financial support for Schwartz Center Rounds in 2004 and then again in 2009.

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made nearly $180 million in grants to local, regional, and national nonprofit organizations that impact society in inspiring and innovative ways. It has also supported disaster relief efforts both domestically and internationally.

About the Schwartz Center for Compassionate Healthcare
The Schwartz Center is a national nonprofit organization that develops and funds innovative programs to promote compassionate care, recognizes and honors caregivers who demonstrate extraordinary compassion in caring for patients and families, and supports policies that promote compassionate care. Its "Agenda for Improving Compassionate Care" was published in the September 2010 issue of Health Affairs, the nation's leading health policy journal. The Center is housed at Massachusetts General Hospital in Boston.

Most Popular Now

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Pfizer's novel COVID-19 oral antiviral treatment c…

Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on a...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Researchers reveal a strategy for next-generation …

A study led by the Garvan Institute of Medical Research has revealed a guide to developing COVID-19 vaccines that both prevent the coronavirus from infecting human cells ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...

A commonly found parasite could treat certain type…

Scientists have discovered that a deadly parasite, known to cause ill health in pregnant women and immunocompromised patients, could potentially be used to treat various ...